INTRODUCTION
Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells (PCs), primarily in the bone marrow. 1 Normal PCs are rare cells in the body, located mainly in the bone marrow (0.5% of bone marrow cells) and mucosa. These normal PCs are quiescent cells in vivo and may survive for years, insuring long-term humoral memory. 2 MM disease is preceded by a several year-lasting premalignant monoclonal gammopathy with undetermined significance (MGUS). 3 MGUS may transform to MM with a 1% rate per year, independent on MGUS duration. 4 MM disease is heterogeneous in terms of molecular abnormalities in malignant PCs, 5 and the use of high throughput methodologies has revealed many genes whose copy number or expression is associated with a difference in patients' treatment response or survival. But the study in depth of the biological role played by deregulated gene products is hampered by the availability of primary healthy or malignant PCs, the difficulty to culture and/or to genetically modify them. This is particularly the case when no tools (recombinant protein or inhibitor) exist to study the function of a gene product. This explains why most biological studies use human myeloma cell lines (HMCLs), which are obtained form a minority of patients with a special MM disease entity, that is, patients with extramedullary proliferation. 6 The biological concepts obtained with these HMCLs could be limited to this minority of patients, in whom malignant PCs are no more or less dependant on the bone marrow environment, likely due to additional deregulations of survival and cell cycle. 7 To further progress in the understanding of MM disease, it is critical to be able to stably introduce a genetic modification into malignant PCs to get a forced expression or knockdown of a gene. It is also important to manipulate PCs, to investigate whether myeloma genes can modify the biology of healthy PCs and transform them into premalignant or malignant PCs.
Whereas vesicular stomatitis virus G (VSV-G) pseudotyped lentiviral vectors (LVs) can transduce HMCLs, 8 they poorly transduce primary malignant PCs, which are weakly cell cycling. We have shown recently that LVs incorporating the Edmonston strain measles virus (MV) with hemagglutinin and fusion glycoproteins (H/F-LVs) can efficiently and stably transduce quiescent human B lymphocytes 9 or T lymphocytes. 10 The MV H glycoprotein binds to signaling lymphocyte activation molecule (SLAMF1/CD150) and to CD46, which are expressed on a subpopulation of quiescent B or T lymphocytes. Transduction of malignant PCs by H/F-LVs should be possible as several reports have documented the ability of oncolytic MV to efficiently infect and kill primary malignant PCs or HMCLs, in particular because malignant PCs express CD46, and this strategy was proposed as a therapeutic option to kill malignant PCs. 11 --13 In this study, we report that H/F-LVs can efficiently transduce primary malignant PCs as well as healthy PCs, where VSV-G-LVs failed. VSV-G-LVs can transduce HMCLs but with a lower efficacy than MV-LVs.
MATERIALS AND METHODS

Cell samples
Bone marrow cells were obtained from 10 patients with MM for routine clinical evaluation of the disease. Excess cells were used after obtaining patients' written informed consent in accordance with the Declaration of Helsinki and agreement of the Center for Biological Resources of Montpellier University Hospital (N1DC-2008-417). Cell cycle profiles of primary malignant PCs were determined using PI staining and the algorithm ModFit was used to assign the different cell cycle phases. 14 For gene expression data, we used Affymetrix U133 plus 2.0 publicly available data of our cohort of 206 newly-diagnosed patients treated with induction treatment and then high dose melphalan and autologous stem cell transplantation (http://www.ebi.ac.uk/arrayexpress, under accession number E-MTAB-362). 15 HMCLs were obtained and characterized in our laboratory. 16 --18 Healthy plasmablasts or PCs were obtained using our three-step in vitro model making it possible to obtain six syndecan-1 þ PCs starting from one circulating memory B cell within 10 days. 19 This threestep model mimics the activation and differentiation processes of B cells mediated at least by T cells and follicular dendritic cells occurring in germinal centers.
Step 1 uses a stimulation by CD40L, CpG oligonucleotide activating Toll-like receptor and T-cell cytokines IL-2, IL-10 IL-15; step 2 a removal of CD40L and Toll-like receptor stimulation to promote plasmablastic differentiation and addition of STAT3 activating cytokines; and step 3 an activation of interferon signaling pathway to promote further PC differentiation.
Plasmids
H and F glycoproteins are from the Edmonston vaccine strain. They were inserted into pCG plasmids under the control of the cytomegalovirus early promoter. Cytoplasmic tails of all H and F proteins were deleted by truncation of 24-and 30-aa, respectively. The pCMV-G plasmid encoding the VSV-G glycoprotein was described previously. 20 
Lentiviral production
Self-inactivating HIV-1-derived vectors were generated by transient transfection of 293T cells in DMEM medium (Invitrogen, Carlsbad, NM, USA) as described. 10 Briefly, for VSV-G pseudotyping 3 mg of the pCMV-G plasmid was transfected and for co-display of the different H and F proteins, 3 mg of each envelope plasmid was transfected together with a gagpol packaging plasmid and a plasmid encoding a LV expressing GFP (SIN-HIVSFFVGFP). Virus was concentrated using overnight low-speed (3000 g at 4 1C) centrifugation of viral supernatant and frozen at À80 1C until use. The transduction efficiency and infectious titers were assayed adding to 293T cells serial concentrations of vector preparation and monitoring GFP þ cells by immunofluorescence. Infectious titers were expressed as 293T transducing units per milliliter (TU/ml) as described. 21 Transduction of healthy and malignant PCs Cells were cultured in RPMI 1640 medium (Invitrogen, Gibco BRL, Cergy Pontoise, France) supplemented with 10% FCS (PAA Laboratory GmbH, Pasching, Austria) and with 2 ng/ml of IL-6 (Abcys SA, Paris, France) for malignant PCs and HMCLs and in the appropriate step culture conditions for healthy in vitro generated PCs. 19 A 2 Â 10 5 cells were seeded per 48-well and were transduced with a multiplicity of infection ranging from 0.125 to 1.5 for HMCLs and up to 7.5 as indicated for malignant or healthy PCs. The percentage of GFP þ cells was determined 72 h after transduction by fluorescence-activated cell sorting (FACS) using a FACScan cytometer (Becton Dickinson (BD), San Jose, CA, USA).
Flow cytometry immunophenotyping
Multiparameter analysis was done with antibodies (mAbs) conjugated to fluorescein (FITC), phycoerythrin (PE), PE-cyanin-7 (PE-Cy7), allophycocyanin (APC) and APC-Alexa 750. Specific mAbs for human CD19 (clone J3-119), CD20 (clone B9E9), CD38 (clone LS198-4-3), CD45 (clone J-33) and CD138 (clone B-A38) were purchased from Beckman Coulter (Fullerton, CA, USA). CD38 (clone HIT2) and CD56 (N-CAM, clone B159) from BD, and CD46 (clone 8E2), CD150 (clone A12(7D4)) and CD200 (clone OX104) from eBioscience (San Diego, CA, USA). Isotype-matched mouse mAbs recognizing no human antigen were used as controls. Flow cytometry immunophenotyping was performed using a multiparameter immunofluorescence technique as indicated. 22 Bone marrow cells, PCs obtained in vitro and HMCLs were labeled with mAbs conjugated to various fluorochromes. Isotype control was used to evaluate the level of background fluorescence on PC populations. Data acquisition was performed with a Cyan flow cytometer driven by Summit 4.3 software (Beckman Coulter) or a FACScan cytometer (BD). Data were analyzed with the Kaluza 1.1 software (Beckman Coulter) or CellQuest (BD). Cell debris and doublets were excluded in the first step. PCs were defined as CD138 þ cells.
Immunofluorescence staining A total of 5 Â 10 4 cells were deposited onto poly-L-lysine-coated slides, fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton. Non-specific staining was blocked by incubating the slides in 5% BSA-PBS, after which the slides were subjected to labelling with the anti-CD138 mAb (Beckman Coulter, clone MI-15) for 1 h in a moist chamber. Slides were then washed with PBS, incubated for 1 h with an Alexafluor 546-conjugated rabbit anti-mouse antibody (Invitrogen, Molecular Probes, Cergy Pontoise, France) in a dark moist chamber. Slides were washed and mounted with Vectashield containing 4 0 -6-Diamidino-2-phenylindole (DAPI) (Sigma Aldrich, St Louis, MO, USA), and examined under an epifluorescence Microscope (Leica Microsystems, Wetzlar, Germany).
Culture of transduced cells
Transduced HMCLs were cultured for 1 month with change of the culture medium every 3 --4 days. Cells were harvested every 7 days for assaying the GFP expression by FACS analysis. Bone marrow mononuclear cells from three patients with MM were transduced with H/F-LVs for 2 days. Cells were washed and malignant PCs together with their bone marrow environment were cultured for 5 days in 200 ml of RPMI1640 culture medium, 10% FCS and IL-6 (2 ng/ml), and the GFP expression was assayed by FACS analysis. The 5 Â 10 5 in-vitro generated healthy PCs harvested at day 7 of culture were transduced with H/F-LVs and cultured for 3 days on 10 4 bone marrow stromal cells generated as indicated 23 in 1 ml of RPMI1640 culture medium, 10% FCS, IL-6 (10 ng/ml) and IFNa (500 U/ml), washed and cultured for 11 days on 10 4 bone marrow stromal cells in 1 ml of RPMI1640 culture medium, 10% FCS and IL-6 (10 ng/ml). The GFP expression was assayed at day 3 and day 14 after H/F-LV transduction by FACS analysis.
Statistical methods
Student's t-test (nX5) was used to evaluate the statistical significance of differences observed between groups for paired and unpaired variables. P values p0.05 were considered to be associated with statistical significance.
RESULTS
Expression of CD46 and SLAMF1/CD150 by healthy and malignant PCs Recently, it was reported that the surface expression of SLAMF1/ CD150 and CD46 MV receptors are absolutely required for primary human lymphocyte transduction. 24 Therefore, we evaluated the presence of both receptors on malignant and healthy PCs. As illustrated for one representative patient in Figure 1a , primary malignant PCs expressed CD46 and SLAMF1/CD150 and this was confirmed for 10 other patients with MM (Figure 1b) . Primary malignant PCs were poorly cell cycling (1.5% of myeloma cells in the S phase of the cell cycle, range 0.8 --3%) (Supplementary Figure S1) . Using a large series of newly diagnosed patients with MM, CD46 and SLAMF1/CD150 genes were expressed (present Affymetrix call) in purified malignant PCs of all patients (Supplementary Figure S1) . Healthy plasmablasts and PCs express both Malignant PCs highly express CD138 and CD38, aberrantly CD56, CD200 or CD117 and did not express CD19 and CD45. 25 Data on Figure 3a show these phenotypic characteristics were not modified by H/F-LV transduction. Indeed GFP þ and GFP À primary malignant PCs from one representative patient displayed similar mean fluorescence intensity for CD138, CD38 and CD200, and lacked CD19 and CD45. A similar phenotypic stability of H/F-LVtransduced primary malignant PCs was found for two other patients' samples. The same holds true for HMCLs, whose phenotype was not affected by H/F-LV transduction ( Table 1) .
Transduction of primary malignant PCs with H/F-LVs was stable. Indeed, GFP expression was maintained in malignant PCs cultured for 1 week together with their bone marrow environment cells in vitro (Figure 4a ). Actually, GFP content increased due to continuous synthesis of stable GFP in poorly proliferating primary malignant PCs. HMCLs were also stably transduced with H/F-LVs, as the GFP expression was maintained after 10 --14 doubling times, that is, one month of culture (Figure 4b ). H/F-LVs also efficiently transduced healthy in-vitro generated plasmablasts or PCs unlike VSV-G-LVs. Respectively, 75% and 39% of healthy plasmablasts and PCs were transduced with H/F-LVs, compared with 19% and 4% for VSV-G-LVs (Pp0.01, Figures 2a --c) . The median mean fluorescence intensity was 10 --20-fold higher with H/F-LVs compared to VSV-G-LVs (Pp0.01). As for malignant PCs, H/F-LV transduction did not modify the phenotype of healthy PCs as both GFP þ and GFP À PCs expressed the same density of CD138, CD38, CD45 or CD19 (Figure 3b ). The transduction of healthy PCs was stable with a maintained GFP expression in PCs cultured for 14 days with stromal cells (Figure 4c ).
DISCUSSION
We show here that measles envelope glycoproteins displaying LVs (H/F-LVs) can efficiently and stably transduce malignant and (a) Malignant PCs of a representative patient sample were transduced with H/F-GFP-LVs (multiplicity of infection, MOI 5) yielding to 21% transduced plasma cells after 3 days of culture. The phenotype of malignant plasma cells was investigated using staining with anti-CD138, CD38, CD200, CD19 or CD45 mAbs. GFP þ transduced malignant plasma cells had the same phenotype as GFP À non-transduced ones. Data are from one patient' s sample representative of three. (b) Healthy plasma cells were generated in vitro and transduced at day 7 with H/F-GFP-LVs (MOI 5). After 3 additional days of culture, 16% healthy plasma cells expressed GFP and their phenotype was investigated using staining with anti-CD138, CD38, CD45, CD19 mAbs. GFP þ healthy plasma cells had the same phenotype as GFP À non-transduced ones. Data are from one healthy plasma cell sample representative of three. The LP1, XG2 and XG20 human myeloma cell lines (HMCLs) were transduced with H/F lentivirus and cultured for 1 month. Data show that transduced HMCLs display the same phenotypic characteristics as non-transduced HMCLs.
healthy PCs, unlike VSV-G pseudotyped LVs. In addition, H/F-LVs did not modify the phenotypic characteristics of healthy or malignant PCs. Both healthy and malignant PCs express the two receptors for measles glycoproteins, SLAMF1/CD150 and CD46, and both receptors were shown to be mandatory to obtain an efficient H/F-LVs transduction in primary lymphocytes. 24 The vast majority of primary malignant PCs (495%) is out of the cell cycle 26 and their efficient transduction by H/F-LVs confirm recent data showing these H/F-LVs can transduce quiescent human primary B or T lymphocytes. 9, 10 The poor transduction of healthy PCs by VSV-G-LVs is not related to cell cycle. Indeed, a poor transduction was observed with high cell cycling 5 in-vitro-generated healthy PCs harvested at day 7 of culture were transduced with H/F-LVs and cultured for 3 days on 10 4 bone marrow stromal cells in 1 ml of RPMI1640 culture medium, 10% FCS, IL-6 (10 ng/ ml) and IFNa (500 U/ml), washed and cultured for additional 11 days on 10 4 bone marrow stromal cells in 1 ml of RPMI1640 culture medium, 10% FCS and IL-6 (10 ng/ml). Data are GFP expression in CD138
þ PCs generated in one experiment representative of three at day 3 and day 14 after H/F-LV transduction assayed by FACS analysis. At least 50% PCs died during the additional 11 days of culture, explaining the lower number of viable CD138 þ PCs 14 days after H/F-LV transduction. Note that GFP content was higher in day 14 PCs due to the accumulation of stable GFP in non-proliferating PCs.
plasmablasts as well as with non-cell cycling PCs, 19 whereas H/F-LVs efficiently transduce both plasmablasts and PCs.
Thus, H/F-LVs provide a powerful tool to stably introduce and express coding DNA in healthy or primary malignant PCs. Many genes whose expression in primary malignant PCs is associated with poor survival are being reported using high throughput microarray methodologies. 7,27 --29 The ability to express these genes in PCs using H/F-LVs will greatly help the understanding of the biological pathways triggered by these gene products and associated with drug resistance and/or poor survival. Another interest will be to confer immunogenicity on primary malignant PCs for the development of immunotherapy strategies, in particular to improve allograft strategies. We and others have shown that malignant PCs of HMCLs are fully efficient to trigger allogenic or autologous cytotoxic T-cell-specific response providing they express immune costimulatory molecules, such as CD80/ B7-1, 4-BB1 ligand or CD40. 30 --32 It is important to extend this finding to primary malignant PCs, introducing these genes using H/F-LVs, in order to promote their use in clinical settings, at least to activate and amplify anti-tumor T cells ex vivo. H/F-LVs should also be promising for the understanding of normal plasma cell biology. Most studies have used murine PCs due to the difficulty to obtain human PCs and to manipulate them. 33 The combination of the ability to generate human PCs in vitro and to efficiently induce the expression of a given gene in these cells should make the study of healthy human PCs far easier. 19 An interesting application will be to immortalize human PCs to produce human monoclonal antibodies specific to a given antigen, introducing the major genes deregulated in malignant PCs and yielding to HMCLs growing in vitro. In conclusion, the finding that LVs pseudotyped with MV envelope glycoproteins enable an efficient and stable introduction and expression of a given gene in noncycling normal and malignant PCs is a major breakthrough, that will further stimulate the study and understanding of the most important mechanisms controlling normal and malignant PC biology.
